中國抗體-B(03681.HK):致譽投資向許斯佳出售8.92%股權
格隆匯 12 月 7日丨中國抗體-B(03681.HK)發佈公告,2020年12月7日,公司獲致譽投資集團有限公司(致譽投資,為公司主要股東)告知,致譽投資已訂立協議,按每股股份3.01港元的價格向獨立第三方許斯佳女士出售合共8980.21萬股公司股份,佔約8.92%公司的已發行股本,總代價為約2.703億港元。
每股股份的代價基於緊接交易前五個交易日的平均收市價釐定。交易完成後,致譽投資於61,500,740股股份中擁有權益,佔約6.11%公司股權,且不再為公司主要股東,而許斯佳女士於89,802,105股股份中擁有權益,佔約8.92%公司股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.